Shang Hai Zheng Quan Bao·2025-12-17 23:08Group 1 - The core announcement is that *ST Meigu (000615) has received court approval for its restructuring plan, which will allow the company to enter the execution phase of the plan and improve its financial structure and operational status [2][8] - The restructuring plan aims to eliminate the company's debt burdens, enhance its corporate image, and focus on the development of its main business [2][8] - If the restructuring is successful, it is expected to significantly impact the company's financial indicators for the year 2025 [2][8] Group 2 - The restructuring process began with a pre-restructuring decision by the Xiangyang Intermediate Court on November 29, 2024, and a restructuring investment agreement was signed on April 23, 2025, between Jiuzhoutong's subsidiary and *ST Meigu [3][9] - A supplementary agreement was signed on September 24, 2025, adjusting the investment terms, where Jiuzhoutong's subsidiary will acquire 435,930,312 shares for a total consideration of 706,207,105.44 yuan [10] - The restructuring investment aligns with Jiuzhoutong's long-term strategic development plan and aims to enhance its core competitiveness in the healthcare sector [4][10] Group 3 - Jiuzhoutong is recognized as the largest private pharmaceutical enterprise in China, with a comprehensive pharmaceutical supply chain service platform [5][10] - Post-restructuring, *ST Meigu plans to leverage the support from its investors to strengthen its existing healthcare services and expand its business into the broader health industry [11]